TY - JOUR
T1 - Elective Neck Dissection in Patients With Head and Neck Adenoid Cystic Carcinoma
T2 - An International Collaborative Study
AU - Amit, Moran
AU - Na’ara, Shorook
AU - Sharma, Kanika
AU - Ramer, Naomi
AU - Ramer, Ilana
AU - Agbetoba, Abib
AU - Glick, Joelle
AU - Yang, Xinjie
AU - Lei, Delin
AU - Bjoerndal, Kristine
AU - Godballe, Christian
AU - Mücke, Thomas
AU - Klaus-Dietrich, Wolff
AU - Eckardt, André M.
AU - Copelli, Chiara
AU - Sesenna, Enrico
AU - Palmer, Frank
AU - Ganly, Ian
AU - Gil, Ziv
N1 - Publisher Copyright:
© 2014, Society of Surgical Oncology.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background: Adenoid cystic carcinoma (ACC) accounts for 3–5 % of all head and neck malignancies. Investigations of outcomes from elective neck dissection (END) for patients with ACC are sparse. This study aimed to assess the impact of END on the survival of patients with ACC. Methods: This retrospective multicentered study investigated 270 patients who underwent neck dissection. A multivariate analysis assessed associations of clinical and histopathologic characteristics with survival outcomes. Results: The primary tumor sites included the oral cavity in 250 patients (55 %), the major salivary glands in 133 patients (29 %), the sinonasal mucosa in 68 patients (15 %), and the larynx in six patients (1 %). The overall rate of occult nodal metastases among the patients who underwent END was 17 % (38/226). The highest incidence of occult nodal metastases was with the oral cavity (66 %). The 5-year overall survival (72 and 79 % for patients with or without END, respectively) and disease-specific survival (74 and 81 % for patients with or without END, respectively) were similar in the two groups. The subgroup analysis of patients according to the primary site showed no significant impact of END on outcome. In the multivariate analysis, primary site, T classification, and N classification were the only variables associated with outcome. Conclusions: The incidence of occult neck metastases among patients with ACC is 17 %. The highest incidence of occult metastases is with the oral cavity. Statistical analysis showed no survival advantage for patients who underwent END compared with those who did not.
AB - Background: Adenoid cystic carcinoma (ACC) accounts for 3–5 % of all head and neck malignancies. Investigations of outcomes from elective neck dissection (END) for patients with ACC are sparse. This study aimed to assess the impact of END on the survival of patients with ACC. Methods: This retrospective multicentered study investigated 270 patients who underwent neck dissection. A multivariate analysis assessed associations of clinical and histopathologic characteristics with survival outcomes. Results: The primary tumor sites included the oral cavity in 250 patients (55 %), the major salivary glands in 133 patients (29 %), the sinonasal mucosa in 68 patients (15 %), and the larynx in six patients (1 %). The overall rate of occult nodal metastases among the patients who underwent END was 17 % (38/226). The highest incidence of occult nodal metastases was with the oral cavity (66 %). The 5-year overall survival (72 and 79 % for patients with or without END, respectively) and disease-specific survival (74 and 81 % for patients with or without END, respectively) were similar in the two groups. The subgroup analysis of patients according to the primary site showed no significant impact of END on outcome. In the multivariate analysis, primary site, T classification, and N classification were the only variables associated with outcome. Conclusions: The incidence of occult neck metastases among patients with ACC is 17 %. The highest incidence of occult metastases is with the oral cavity. Statistical analysis showed no survival advantage for patients who underwent END compared with those who did not.
UR - http://www.scopus.com/inward/record.url?scp=84925501041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925501041&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-4106-7
DO - 10.1245/s10434-014-4106-7
M3 - Article
C2 - 25249259
AN - SCOPUS:84925501041
SN - 1068-9265
VL - 22
SP - 1353
EP - 1359
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -